

**Meningococcal Conjugate Vaccine B**  
**(Minimum age: 10 years)**  
**MenB-4C, Bexsero; MenB-FHbp, Trumenba)**

<b>Pathophysiology</b>	Bacteria
<b>Vaccine Description</b>	Inactivated conjugate vaccine, containing <i>Neisseria meningitidis</i> serogroup B.
<b>Dose &amp; Route</b>	0.5 mL given IM
<b>Administration</b>	<p><b>Shared Clinical Decision-Making</b>          Adolescents not at increased risk age 16-23 years (preferred age 16-18 years) based on shared clinical decision-making:</p> <ul style="list-style-type: none"> <li>• Bexsero: 2-dose series at least 1 month apart</li> <li>• Trumenba: 2-dose series at least 6 months apart; if dose 2 is administered earlier than 6 months, administer a 3<sup>rd</sup> dose at least 4 months after dose 2</li> </ul> <p><b>Special Situations</b>          Anatomic or functional asplenia (including sickle cell disease), persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use, and microbiologists routinely exposed to <i>Neisseria meningitidis</i>:</p> <ul style="list-style-type: none"> <li>• Bexsero: 2-dose series at least 1 month apart</li> <li>• <b>Trumenba®: 3-dose series at 0, 1-2, 6 months (if dose 2 was administered at least 6 months after dose 1, dose 3 not needed; if dose 3 is administered earlier than 4 months after dose 2, a 4th dose should be administered at least 4 months after dose 3)</b></li> </ul> <p>MenB-4C and MenB-FHbp are not interchangeable (use same product for all doses in series); 1 dose MenB booster 1 year after primary series and revaccinate every 2-3 years if risk remains.</p> <p>Pregnancy: Delay MenB until after pregnancy unless at increased risk and vaccination benefits outweigh potential risk.</p> <p>For MenB booster dose recommendations for groups listed under “Special situations” and in an outbreak setting (e.g., in community or organizational settings and among men who have sex with men) and additional meningococcal vaccination information, see <a href="https://www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm">https://www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm</a></p>
<b>Contraindications</b>	<ul style="list-style-type: none"> <li>• Severe allergic reaction after a previous dose of Trumenba.</li> <li>• Hypersensitivity, including severe allergic reaction, to any component of the vaccine, or after a previous dose of BEXSERO.</li> </ul>
<b>Precautions</b>	<ul style="list-style-type: none"> <li>• The tip caps for of the pre-filled Bexsero syringes contain natural rubber latex which may cause allergic reactions in latex sensitive individuals.</li> </ul>